We’ve got a few exciting announcements coming up! Be among the first to hear by subscribing to our newsletter: 📸: Chordoma survivor Craig with Dr. Gondi of @NorthwesternMed

Congrats to Dr. Ke Pan of MD Anderson for being the newest grantee jointly funded by our partnership with @CancerResearch! His project aims to lay the groundwork for a new, brachyury-targeting immunotherapy strategy that could hold promise for chordoma patients. More:.

We're honored to be included in @Newsweek's spotlight on patient-led organizations making strides in rare disease research!. The article underscores the critical role that patient communities play in motivating collaboration, overcoming barriers, and building vital infrastructure.

More than 140 experts from around the world came together last week to work toward improving the standard of care for chordoma via upcoming updated consensus guidelines -- a remarkable effort. Grateful to @alegronchi, @AOSpine & all who participated!.

We're happy to share that @MSKCancerCenter has opened enrollment for a clinical trial evaluating @Erasca's experimental drug ERAS-601 in patients with advanced chordoma. Exciting example of our ability to rapidly translate discoveries from the lab to patients made possible by.

RT @sommerjo: Excited to add this role to the CF team. The aim is to expand the pipeline of therapies in development for chordoma by allowi….

🗣️ We're hiring a Director of Preclinical Research! This is an exciting opportunity for an oncology R&D leader to make a tangible impact in the lives of patients in urgent need of new treatment options. More info:

When we launched the TBXT Challenge (, we hoped it would spark new ideas for stopping brachyury (TBXT) -- a key driver of chordoma -- and attract innovators who might not otherwise focus on our rare disease. It’s been thrilling to see that come to life,.

This week, we launched a survey of chordoma patients and caregivers to better understand their needs, preferences, and priorities related to clinical trials. This reflects our deep belief that patient-centered research and care is essential to driving meaningful progress.

We’re excited to be #hiring for several new roles to advance our mission. Right now, we’re looking for a Clinical Trial Navigator to help chordoma patients find and access promising trials, a Sr. Development Operations Manager to support our fundraising efforts, and a contract.

We're happy to share that @PyxisOncology's Phase 1 trial of PYX-201 (Micvotabart pelidotinaka “MICVO”) has opened to patients with sarcomas, including chordoma: This opportunity came about in part from a discovery made using tumor tissue from our Biobank,.

Our latest Annual Report is here: 🎉 As you'll read, advances in the past year are unlocking vast new possibilities for chordoma treatment. We're deeply grateful to everyone who made 2024 our most impactful year yet, and we're excited to continue this.

Clinicians and researchers: the Canadian International Sarcoma Symposium is coming up May 8-9, and will feature a dedicated session on chordoma. Virtual and in-person options available. More info:

RT @sommerjo: Significant milestone for chordoma research and drug development. Deeply grateful to everyone who came together to make it ha….

RT @sommerjo: Chordoma's most important target, TBXT (brachyury), has long been considered undruggable. Lots of emerging AI approaches and….

Thrilled to announce the launch of our TBXT Challenge, offering $500K+ in prizes to companies and research teams to accelerate TBXT (brachyury) targeted therapies. Excited for drug discovery innovators to enter this challenge, and very grateful to our supporters (incl.

RT @MateiBanu: Very grateful to the @ChordomaFDN for funding our work using spatial multi-omics on matched primary and recurrent chordoma t….

RT @ItaiYanai: I'm very grateful to the Chordoma Foundation for funding our lab's goal of uncovering chordoma cell states and the transitio….

🔬 $2M in new science happening! Through 9 newly funded projects, our grantees aim to: .- Uncover new ways to exploit TBXT (brachyury).- Position chordoma patients to benefit from emerging treatment modalities.- Illuminate new, more personalized treatment strategies. Grateful to

Proud moment for our research team! Our scientists earned recognition at this year's @ctosociety meeting, the main international sarcoma research conference:. 🎙️Nindo Punturi delivered our lab's first-ever invited oral presentation at a major conference. 🏆 Posters presented by